SCHEMBL6763908

SCHEMBL6763908

CCCCC(=O)Oc1c(O)cc(C(=O)O)c(C(=O)CCCC)c1OC(=O)CCCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ RECQL P46063 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ FFAR1 O14842 1/20 0.42
▸ PLA2G2A P14555 1/20 0.42
▸ PLA2G5 P39877 1/20 0.42
▸ HTT P42858 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ NR4A1 P22736 1/20 0.38
▸ PAK1 Q13153 1/20 0.38
▸ ELANE P08246 3/20 0.36
▸ LDHA P00338 1/20 0.36
▸ LDHB P07195 1/20 0.36
▸ AKR1B1 P15121 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6762847 0.96 PLA2G2A (0.48) MEN1KMT2ARECQLKDM4EFFAR1
SCHEMBL6759815 0.95 PLA2G2A (0.50) MEN1KMT2ARECQLKDM4EFFAR1
SCHEMBL6764160 0.89 RECQL (0.45) MEN1KMT2ARECQLKDM4EFFAR1
SCHEMBL6761434 0.87 FFAR1 (0.40) MEN1KMT2ARECQLKDM4EFFAR1
SCHEMBL6762751 0.86 NR4A1 (0.44) FFAR1PLA2G2APLA2G5HTTALDH1A1
SCHEMBL6762901 0.85 ESR1 (0.44) ALDH1A1TSHRHSD17B10TDP1
SCHEMBL6761222 0.85 NR4A1 (0.40) FFAR1PLA2G2APLA2G5ALDH1A1NR4A1
SCHEMBL6759839 0.84 TSHR (0.45) FFAR1PLA2G2APLA2G5ALDH1A1TSHR
SCHEMBL6766244 0.83 PLA2G2A (0.46) MEN1KMT2AFFAR1PLA2G2APLA2G5
SCHEMBL6761532 0.82 NR4A1 (0.48) MEN1KMT2AFFAR1PLA2G2APLA2G5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040247698-A1 Erectile Dysfunction Treatment VALENZUELA CORTES CARMEN MARIA (CL) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040247698-A1 Erectile Dysfunction Treatment PDE3A, PDE3B, PDE12 MEN1 3117/4885KMT2A 2816/4885RECQL 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback